人福医药：屈螺酮炔雌醇片获批

Core Viewpoint - The approval of the drug "Drosperinone and Ethinyl Estradiol Tablets" by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell the product in the domestic market and enhancing its product line [1] Group 1 - The company's subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., received the drug registration certificate for Drosperinone and Ethinyl Estradiol Tablets [1] - The drug is intended for female contraception and the company submitted its application for marketing authorization in March 2024, which has been accepted [1] - The total R&D investment for this product amounts to approximately RMB 8.5 million [1] Group 2 - The projected national sales revenue for Drosperinone and Ethinyl Estradiol Tablets in 2024 is approximately RMB 320 million [1] - The approval signifies the company's qualification to market the drug domestically, which is expected to have a positive impact on its business [1]